At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
LY3023414drug
Likely dose
LY3023414 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single-Arm, Open-Label, Phase II Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
In Brief
A Phase 2 clinical trial evaluating LY3023414 for Endometrial Cancer and Recurrent Endometrial Cancer. Completed, enrolled 28 participants across 6 sites.
Detailed Summary
The purpose of this study is to determine the effectiveness of LY3023414 in treating the participants type of cancer and to determine the types and severity of side effects caused by treatment with LY3023414.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Cancer, Recurrent Endometrial Cancer
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedSep 2015
Primary CompletionMar 2022
TodayJul 2026
First PostedSep 15, 2015
Enrollment StartSep 1, 2015
Primary CompletionMar 23, 2022
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 10.8 years ago
Interventions
LY3023414drug
Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination